Sathi Sathiyaseelan

Akston Biosciences Corp. engages in the development of biologic therapeutics for use in autoimmune Type 1 diabetes prevention. It offers novel vaccine, disrupt insulin autoimmunity to prevent type 1 diabetes, and controlled hypoglycemia to enhance anti-tumor cancer therapy. The company was founded by Todd C. Zion in 2011 and is headquartered in Beverly, MA.

Akston Biosciences Corp. engages in the development of biologic therapeutics for use in autoimmune Type 1 diabetes prevention. It offers novel vaccine, disrupt insulin autoimmunity to prevent type 1 diabetes, and controlled hypoglycemia to enhance anti-tumor cancer therapy. The company was founded by Todd C. Zion in 2011 and is headquartered in Beverly, MA.

Akston Biosciences Corp. engages in the development of biologic therapeutics for use in autoimmune Type 1 diabetes prevention. It offers novel vaccine, disrupt insulin autoimmunity to prevent type 1 diabetes, and controlled hypoglycemia to enhance anti-tumor cancer therapy. The company was founded by Todd C. Zion in 2011 and is headquartered in Beverly, MA.

Akston Biosciences Corp. engages in the development of biologic therapeutics for use in autoimmune Type 1 diabetes prevention. It offers novel vaccine, disrupt insulin autoimmunity to prevent type 1 diabetes, and controlled hypoglycemia to enhance anti-tumor cancer therapy. The company was founded by Todd C. Zion in 2011 and is headquartered in Beverly, MA.

Akston Biosciences Corp. engages in the development of biologic therapeutics for use in autoimmune Type 1 diabetes prevention. It offers novel vaccine, disrupt insulin autoimmunity to prevent type 1 diabetes, and controlled hypoglycemia to enhance anti-tumor cancer therapy. The company was founded by Todd C. Zion in 2011 and is headquartered in Beverly, MA.